Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report

Ismail Simsek; Salih Pay; Ayhan Dinc; Hakan Erdem; Bulent Kurt

doi:10.1007/s10067-006-0454-4

Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report

Clin Rheumatol. 2007 Sep;26(9):1561-2. doi: 10.1007/s10067-006-0454-4. Epub 2006 Oct 24.

Authors

Ismail Simsek¹, Salih Pay, Ayhan Dinc, Hakan Erdem, Bulent Kurt

Affiliation

¹ Division of Rheumatology, Department of Medicine, Gülhane Military School of Medicine, Etlik/Ankara, 06018, Turkey. [email protected]

PMID: 17061154
DOI: 10.1007/s10067-006-0454-4

Abstract

Ever since the introduction of anti-tumor necrosis factor (TNF) agents, concerns have been raised regarding their potential for developing malignancy. We report the development of thymic atypical carcinoid tumor 9 months after the initiation of etanercept therapy in a patient having refractory spondylarthritis. This case indicates the need for following large cohorts of patients receiving anti-TNF agents to address the long-term effect of these agents on malignancies.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal / adverse effects*
Carcinoid Tumor / chemically induced*
Etanercept
Humans
Immunoglobulin G / adverse effects*
Male
Pituitary ACTH Hypersecretion / etiology
Receptors, Tumor Necrosis Factor
Spondylarthritis / drug therapy
Thymus Neoplasms / chemically induced*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Etanercept